小黃鴨德盈(02250.HK)與復星國際旗下基金成立合資公司
小黃鴨德盈(02250.HK)公布,間接全資附屬公司德盈文旅,與復星國際(00656.HK)旗下從事創業投資業務的基金南鋼星博,訂立合作框架協議及合資協議,成立合資公司,共同開發基於IP的娛樂和零售項目。
其中德盈文旅以現金出資2,250萬元人民幣(下同),佔合資公司註冊資本總額的60%,而南鋼星博以現金出資1,500萬元,佔合資公司註冊資本總額的40%;另外,雙方訂立合資補充協議,授予南鋼星博出售選擇權。
集團指,合資公司將主要依托小黃鴨IP和復星國際文旅資源從事IP文旅樂園、文旅項目拓展、IP衍生品零售等業務。將充分運用小黃鴨IP專注於文旅實景IP授權商業化場景的打造、線上線下渠道的拓展與營運業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.